Skip to content

Author

H. Heyn

We have 8 of 224 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Site-specific immune remodeling underlies resistance to dual immune checkpoint blockade in metastatic colorectal cancer

Findings show that resistance to ICI in liver metastases arises from tissue-specific misdirection of immune activation away from productive antitumor immunity, identifying multicellular coordination of the immune response in the metastatic microenvironment as a determinant of therapeutic efficacy.

I. Baraibar, S. Morabito, G. Deuner-Cos et al. · 0 citations
Open access Sep 2026

p38α orchestrates BRAFV600E-melanoma progression and immunotherapy response via tumor fitness and immune microenvironment modulation

It is reported that, in an UVB induced Braf V600E-mutated spontaneous mouse melanoma model, p38α contributes to tumor fitness and anti-tumor immune responses, showing that p38α inhibition sensitizes tumors to anti-PD1.

Paula Granado-Martínez, K. McGrail, Roberto Orsenigo et al. · 0 citations
Open access Sep 2026

Uncovering combination therapies for immune-mediated inflammatory diseases through systems biology analysis on longitudinal patient data.

It is shown that longitudinal patient data help prioritize drug combinations for clinical testing across immune-mediated diseases, and anti-TNF and anti-interleukin 6 receptor therapy emerges as highly complementary in rheumatoid arthritis.

S. Martínez-Mateu, Y. Guillén, Edgar Angelats et al. · 1 citation
Open access Sep 2026

Personalized neoantigen vaccine platform and longitudinal tracking of vaccine-related clonotypes enable the identification of tumor-specific TCRs

This proof-of-concept study demonstrates that personalized neoantigen vaccination can induce durable and diverse tumor-specific T-cell responses in ovarian cancer and establishes a framework for using vaccination as an in vivo platform to identify clinically relevant tumor-specific TCRs for future cellular therapies.

Laurent Beziaud, P. Szturz, A. Sarivalasis et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.